Weihao Xu
Founder & Chief Executive Officer Kali Therapeutics
Weihao Xu is Founder and Chief Executive Officer of Kali Therapeutics, where he leads the company’s strategy to develop next-generation biologics and immune-resetting therapies for autoimmune and inflammatory diseases. Prior to founding Kali Therapeutics, Weihao held multiple senior roles at Harbour BioMed, including Chief Business Officer, Chief Financial Officer, and President of U.S. operations, where he led global partnerships, corporate development, and strategic growth initiatives. Earlier in his career, he served as Chief Financial Officer at Alphamab Oncology and held roles in investment management, focusing on global healthcare and life sciences. Weihao has a strong track record of building and scaling biotech organizations, executing strategic transactions, and advancing innovative therapeutic platforms toward clinical development.
Seminars
- Discussing approaches to differentiate assets targeting competitive targets
- With clinical data so far, what constitutes a good outcome in autoimmune disease and which approach gets you there?
- Protocol design to define initial target indications, strategizing how to rapidly generate early clinical, proof-of-concept data, and differentiating company assets within competitive landscapes
